Insulet - PODD Stock Forecast, Price & News

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PODD. Piper Sandler raised their price objective on shares of Insulet from $230.00 to $235.00 and gave the stock a "neutral" rating in a report on Friday, August 5th. Raymond James raised their price objective on shares of Insulet from $262.00 to $280.00 in a report on Friday, August 5th. Canaccord Genuity Group raised their target price on shares of Insulet from $250.00 to $290.00 and gave the company a "buy" rating in a research note on Friday, August 5th. Citigroup raised their target price on shares of Insulet to $260.00 in a research note on Tuesday. Finally, BTIG Research raised their target price on shares of Insulet to $285.00 in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $295.23.

Insulet Trading Up 2.5 %

Shares of Insulet stock opened at $270.70 on Friday. The company's fifty day simple moving average is $231.79 and its 200-day simple moving average is $237.12. The stock has a market capitalization of $18.79 billion, a PE ratio of 541.40 and a beta of 0.73. Insulet has a 1-year low of $181.00 and a 1-year high of $324.81. The company has a debt-to-equity ratio of 3.28, a current ratio of 4.69 and a quick ratio of 4.51.

Insulet (NASDAQ:PODD - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.50) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.72). The business had revenue of $299.40 million for the quarter, compared to analysts' expectations of $290.87 million. Insulet had a return on equity of 13.83% and a net margin of 2.94%. The company's revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. As a group, equities analysts anticipate that Insulet will post 0.87 earnings per share for the current year.

Insider Transactions at Insulet

In related news, COO Charles Alpuche sold 6,000 shares of Insulet stock in a transaction on Monday, June 6th. The shares were sold at an average price of $215.32, for a total transaction of $1,291,920.00. Following the transaction, the chief operating officer now owns 43,899 shares in the company, valued at approximately $9,452,332.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, COO Charles Alpuche sold 6,000 shares of Insulet stock in a transaction on Monday, June 6th. The shares were sold at an average price of $215.32, for a total transaction of $1,291,920.00. Following the transaction, the chief operating officer now owns 43,899 shares in the company, valued at approximately $9,452,332.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Shacey Petrovic sold 15,000 shares of Insulet stock in a transaction on Friday, July 1st. The shares were sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the transaction, the director now owns 13,695 shares in the company, valued at approximately $3,052,615.50. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company's stock.